NCT01829971: A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection |
|
|
| Terminated | 1 | 155 | US, RoW | MRX34 | Mirna Therapeutics, Inc., Cancer Prevention Research Institute of Texas | Primary Liver Cancer, SCLC, Lymphoma, Melanoma, Multiple Myeloma, Renal Cell Carcinoma, NSCLC | 03/17 | 05/17 | | |
